With a view to starting in Holguín the application of Emicizumab, an innovative drug that acts prophylactically in patients with Hemophilia A, a team of professionals from the Lucía Íñiguez Landín Clinical Surgical Hospital, made up of hematologists, residents, nurses in charge of its administration and pharmacy personnel, received an online training, on the particularities of the treatment.
This northeastern territory will make its first foray into its use with the care of a patient with Severe Hemophilia A, a hereditary bleeding disorder characterized by a deficiency of blood coagulation factor VIII. This factor is essential in the clotting process, helping to form clots and stop bleeding.
Preparation, professionals of the Hospital Lucía, Holguín
During the training they were able to exchange with leading specialists in the country and in the Caribbean region, leaders in the use of the new drug. Among them were Dr. C. Dunia Castillo Gonzalez, Specialist of I and II degree in Hematology; Leslie Gonzalez Gonzalez Gonzalez, medical leader in Hemophilia in Central America and the Caribbean and Miriam Vilaragut Garcia, Commercial of Roche Farma.
Gertrudis Rodríguez Rodríguez, Head of the Hematology Service of the medical institution, and health personnel who will be in charge of the administration of the biotechnological product were present on the Holguin side.
During the meeting, the importance of establishing close collaboration between the Hematology and Pharmacy departments was discussed. Likewise, reference was made to how the understanding between both teams will guarantee the correct coordination in the delivery, administration and follow-up of the drug.
This is not only a new drug, but also a fresh experience in the therapeutic approach to Hemophilia A, where those affected may experience spontaneous or excessive bleeding after injuries or surgeries, joint hemorrhages with the presence of pain and inflammation, easy bruising and prolonged bleeding after cuts or dental procedures.
So this first step in the application of Emicizumab in Holguín represents a milestone in the medical attention of the institution and especially for those who suffer from this condition. Undoubtedly, it is an opportunity to have an impact on their quality of life, being a hope that will give them back an active and full social life.
Hemophilia A is inherited recessively, linked to the X chromosome, which means that it mainly affects males. The bibliography consulted refers that although women can be carriers, they rarely present mild symptoms. The diagnosis is made through blood tests that measure the levels of coagulation factors.
In the case of hemophilia A, a decrease in factor VIII is observed. Therefore, the main lines of treatment are aimed at supplying concentrates of this factor to prevent or control hemorrhagic episodes. This chronic condition requires continuous medical attention, but with proper treatment, affected individuals can lead an active life.
- Optimization of medical services with technological platforms - 12 de August de 2024
- World Breastfeeding Week developed in Holguin - 8 de August de 2024
- Holguín professionals trained for the application of Emicizumab - 27 de July de 2024